Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Everest Medicines Ltd. ( (HK:1952) ) is now available.
Everest Medicines Ltd. has entered into an agreement with Visara, Inc. to develop and commercialize VIS-101, a novel bifunctional biologic, in Greater China and other Asian markets. This strategic collaboration allows Everest Medicines to expand into the ophthalmology sector, adding a commercially attractive asset to its late-stage product pipeline, potentially enhancing its market positioning and addressing significant unmet medical needs in the region.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. operates in the biopharmaceutical industry, focusing on developing and commercializing innovative medicines. The company is expanding its product pipeline with a focus on late-stage products, and it is now entering the ophthalmology sector, which has significant unmet medical needs.
Average Trading Volume: 5,108,332
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.27B
See more insights into 1952 stock on TipRanks’ Stock Analysis page.